143 related articles for article (PubMed ID: 32930121)
41. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
[TBL] [Abstract][Full Text] [Related]
42. Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer.
Nakagawa K; Hida T; Nokihara H; Morise M; Azuma K; Kim YH; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Kumagai T; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Koyama R; Mitsudomi T; Yamamoto N; Asakawa T; Hayashi M; Hasegawa W; Tamura T
Lung Cancer; 2020 Jan; 139():195-199. PubMed ID: 31812890
[TBL] [Abstract][Full Text] [Related]
43. NCAPH is negatively associated with Mcl‑1 in non‑small cell lung cancer.
Xiong Q; Fan S; Duan L; Liu B; Jiang X; Chen X; Xiong C; Tao Q; Wang J; Zhang H; Chen C; Duan Y
Mol Med Rep; 2020 Oct; 22(4):2916-2924. PubMed ID: 32945371
[TBL] [Abstract][Full Text] [Related]
44. Duplex value of caveolin-1 in non-small cell lung cancer: a meta analysis.
Chen D; Shen C; Du H; Zhou Y; Che G
Fam Cancer; 2014 Sep; 13(3):449-57. PubMed ID: 24609521
[TBL] [Abstract][Full Text] [Related]
45. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis.
Wu B; Sun C; Feng F; Ge M; Xia L
J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234
[TBL] [Abstract][Full Text] [Related]
46. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
47. KRAS Mutation as a Biomarker for Survival in Patients with Non-Small Cell Lung Cancer, A Meta-Analysis of 12 Randomized Trials.
Ying M; Zhu XX; Zhao Y; Li DH; Chen LH
Asian Pac J Cancer Prev; 2015; 16(10):4439-45. PubMed ID: 26028111
[TBL] [Abstract][Full Text] [Related]
48. Pharmacogenetic Association between
Zhang N; Ouyang Y; Chang J; Liu P; Tian X; Yu J
Biomed Res Int; 2020; 2020():3520764. PubMed ID: 33150172
[TBL] [Abstract][Full Text] [Related]
49. AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases.
Wu X; Ma W; Zhou Q; Yan H; Lim ZF; Huang M; Deng C; Yu X; Su H; Komo S; Yang H; Zhang X; Wen S; Zhang Z; Ma PC
J Cancer Res Clin Oncol; 2017 Oct; 143(10):1947-1957. PubMed ID: 28551766
[TBL] [Abstract][Full Text] [Related]
50. KRAS mutation as a prognostic factor and predictive factor in advanced/metastatic non-small cell lung cancer: A systematic literature review and meta-analysis.
Goulding RE; Chenoweth M; Carter GC; Boye ME; Sheffield KM; John WJ; Leusch MS; Muehlenbein CE; Li L; Jen MH; Rojubally A; Jansen J; Druyts E
Cancer Treat Res Commun; 2020; 24():100200. PubMed ID: 32750661
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 over-expression is associated with a poor prognosis in Asian non-small cell lung cancer patients.
Xia H; Shen J; Hu F; Chen S; Huang H; Xu Y; Ma H
Clin Chim Acta; 2017 Jun; 469():191-194. PubMed ID: 28188721
[TBL] [Abstract][Full Text] [Related]
52. The roles of MASPIN expression and subcellular localization in non-small cell lung cancer.
Wang XF; Liang B; Zeng DX; Lei W; Chen C; Chen YB; Huang JA; Gu N; Zhu YH
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32391558
[TBL] [Abstract][Full Text] [Related]
53. Disparate outcomes in nonsmall cell lung cancer by immigration status.
Chau B; Ituarte PH; Shinde A; Li R; Vazquez J; Glaser S; Massarelli E; Salgia R; Erhunmwunsee L; Ashing K; Amini A
Cancer Med; 2021 Apr; 10(8):2660-2667. PubMed ID: 33734614
[TBL] [Abstract][Full Text] [Related]
54. Relationship between NOB1 expression and prognosis of resected non-small cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Biol Markers; 2015 Feb; 30(1):e43-8. PubMed ID: 25450647
[TBL] [Abstract][Full Text] [Related]
55. The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis.
Wu Y; Liu HB; Ding M; Liu JN; Zhan P; Fu XS; Lu G
Mol Biol Rep; 2012 Oct; 39(10):9621-8. PubMed ID: 22729914
[TBL] [Abstract][Full Text] [Related]
56. The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis.
Gong T; Liu J; Jiang J; Zhai YF; Wu CM; Ma C; Wen BL; Yan XY; Zhang X; Wang DM; Lu Q; Qu YL
Cell Mol Biol (Noisy-le-grand); 2019 Jan; 65(1):89-93. PubMed ID: 30782303
[TBL] [Abstract][Full Text] [Related]
57. Prognostic value of pretreatment prognostic nutritional index in non-small cell lung cancer: A systematic review and meta-analysis.
Hu Y; Shen J; Liu R; Feng Z; Zhang C; Ling L; Chen L
Int J Biol Markers; 2018 Nov; 33(4):372-378. PubMed ID: 30282502
[TBL] [Abstract][Full Text] [Related]
58. Efficacy of PD-1/PD-L1 inhibitors in patients with advanced non-small cell lung cancer: A meta-analysis of randomized clinical trials.
Peng TR; Wu TW
Thorac Cancer; 2019 May; 10(5):1176-1181. PubMed ID: 30969033
[TBL] [Abstract][Full Text] [Related]
59. Efficacy of Tumor Vaccines and Cellular Immunotherapies in Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Dammeijer F; Lievense LA; Veerman GD; Hoogsteden HC; Hegmans JP; Arends LR; Aerts JG
J Clin Oncol; 2016 Sep; 34(26):3204-12. PubMed ID: 27432922
[TBL] [Abstract][Full Text] [Related]
60. Prognostic significance of nuclear Yes-associated protein 1 in patients with nonsmall cell lung cancer: A systematic review and meta-analysis.
Zhu L; Ma G; Liu J; Deng Y; Wu Q; Chen W; Zhou Q
Medicine (Baltimore); 2019 Apr; 98(16):e15069. PubMed ID: 31008931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
